As per MRFR analysis, the Cell and Gene Therapy Market Size was estimated at 9.34 (USD Billion) in 2023. The Cell and Gene Therapy Market is expected to grow from 10.47 (USD Billion) in 2024 to 37 (USD Billion) by 2035. The Cell and Gene Therapy Market CAGR (growth rate) is expected to be around 12.16% during the forecast period (2025 - 2035).
The rising incidence of chronic illnesses and genetic disorders, along with biotechnology breakthroughs, are propelling the market for cell and gene therapy. The growing need for personalized medicine, which customizes therapies based on the unique characteristics of each patient, is a major market driver.
This move to more tailored care increases the efficacy of medication and reduces side effects, which is why it is so important to the growth of the market.
A strong atmosphere for innovation is also produced by encouraging government programs and financial assistance for studies into gene-based and cellular medicines. One of the market's opportunities is the creation of innovative treatments for diseases that were previously incurable.
There is a great deal of promise for gene therapy breakthroughs due to the focus on uncommon diseases, especially those with genetic causes. The field is poised for expansion as a result of partnerships between academic institutions and biotech companies that create opportunities for research and commercialization.
To increase effectiveness, there has been a noticeable tendency in recent years to combine gene and cell therapies with other forms of treatment, like immunotherapies and CRISPR technologies. Regulators in a number of nations are expediting the approval procedures for novel treatments, which speeds up market entry.
Additionally, the development of sophisticated manufacturing procedures is lowering costs by increasing the efficiency of production pipelines. These patterns reflect a dynamic environment that is set to undergo major change in the years to come as the cell and gene therapy market continues to develop.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The prevalence of genetic disorders is on the rise globally, driving the demand for cell and gene therapies. According to the World Health Organization, approximately 1 in 1,600 births is affected by a congenital disorder, translating to millions of infants born with genetic disorders each year worldwide.
This growing patient base highlights the urgent need for innovative therapeutic solutions, thereby bolstering the Cell and Gene Therapy Market. Organizations such as the National Institutes of Health are actively funding Research and Development initiatives focused on new gene therapies to combat these disorders.
With increased investment and collaborative efforts among industry stakeholders, the market for gene therapies targeting genetic disorders is set to expand significantly, creating new opportunities for growth within the Cell and Gene Therapy Market.
Technological advancements in Research and Development are significant drivers for the expansion of the Cell and Gene Therapy Market. The advancements in genome editing technologies, such as CRISPR-Cas9, have revolutionized the approach to developing therapies, enabling precise alterations to genetic material.
In a report published by the U.S. National Institute of Health, over 65 clinical trials utilizing CRISPR technology are ongoing, showcasing the momentum that such innovations bring to the market.
These developments not only improve treatment efficacy but also open pathways for the introduction of novel therapies, fostering significant growth opportunities within the Cell and Gene Therapy Market landscape.
The Cell and Gene Therapy Market is experiencing a surge in investment in biopharmaceutical companies that are focusing on innovative treatment solutions. In the last year alone, venture capital investments in biotech firms reached over USD 20 billion globally, with a significant portion directed towards those specializing in gene therapy and regenerative medicine.
Institutions such as the Biotechnology Innovation Organization are focusing on nurturing these companies to ensure they have the necessary resources to advance their developmental pipelines.
Large pharmaceutical companies are also entering partnerships with biotech firms to leverage their technological advancements, which is likely to bolster the Cell and Gene Therapy Market as new therapies are brought to market more efficiently.
The Cell and Gene Therapy Market showed remarkable potential, particularly within the Therapy Type segment, which includes Cell Therapy, Gene Therapy, and Combination Therapy. The market was characterized by its rapid growth as it addresses unmet medical needs.
Among the three main types of therapies, Cell Therapy generated a valuation of 4.19 USD Billion in 2024, increasing to 14.6 USD Billion by 2035, thus holding a majority share in the market due to its effectiveness in treating various chronic and degenerative diseases. This segment played a crucial role in regenerative medicine, driving innovation and attracting investment.
Gene Therapy, valued at 5.14 USD Billion in 2024 and anticipated to reach 18.28 USD Billion by 2035, also represented a significant portion of the market. Technology allowed for precise targeting of genetic defects, making it indispensable for conditions that have previously lacked effective treatment options.
Furthermore, Combination Therapy, which encompassed the use of both cell and gene strategies, was valued at 1.14 USD Billion in 2024, growing to 4.12 USD Billion by 2035, showcasing its importance in offering synergistic effects that can lead to enhanced therapeutic outcomes.
This segment was critical as it combined multiple therapeutic mechanisms, enhancing efficacy and offering broader treatment possibilities for patients. The overall Cell and Gene Therapy Market data indicated a strong interest in innovative therapies that provide alternatives to traditional treatment methods.
The market growth is expected to be driven by an increase in incidences of chronic diseases, advancements in technology, and greater funding from both public and private sectors. Challenges such as regulatory hurdles and high manufacturing costs remain prevalent, but the opportunities in this evolving market are vast, with ongoing breakthroughs that promise more effective treatments.
The Cell and Gene Therapy Market statistics illustrate the ongoing shift towards personalized medicine, reflecting a broader trend in healthcare that prioritizes tailored treatment approaches.
As researchers and clinicians continue to explore the benefits of each therapy type, the landscape of this market is likely to transform significantly in the coming years, further contributing to the healthcare system.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Growth in the segment is driven by the rising prevalence of diseases such as Oncology, Genetic Disorders, Cardiovascular Diseases, and Infectious Diseases. Oncology applications are particularly crucial, as cancer treatments are evolving rapidly with cell and gene therapies, offering new hope for patients.
Genetic Disorders also represent a significant area, as advancements in gene editing technologies pave the way for potential curative therapies. The importance of cardiovascular disease applications is escalating, given the increasing prevalence of heart conditions, calling for effective therapeutic solutions.
Likewise, the focus on infectious diseases has intensified, especially post-pandemic, with gene therapies showing promise in combating viral infections. Overall, the Cell and Gene Therapy Market segmentation illustrates a diverse range of therapeutic applications, indicating a robust demand driven by the need for innovative treatments.
The market growth is underpinned by factors such as heightened investment in Research and Development, collaborative efforts among pharmaceutical companies, and supportive regulatory environments that encourage innovation.
The End-Use segment showcases significant diversity, especially among various sectors including Hospitals, Research Institutions, Pharmaceutical Companies, and Biotechnology Companies. Hospitals serve as a crucial area for cell and gene therapy implementation, addressing patient-specific needs and enhancing treatment options.
Research Institutions play a vital role in advancing innovative therapies, conducting essential Research and Development that drives the market forward. Pharmaceutical Companies are essential for the commercialization of therapies, leveraging their extensive distribution channels to bring products to market.
Biotechnology Companies focus on cutting-edge technology and novel treatment approaches, often pioneering new therapies that cater to unmet medical needs. Overall, the Cell and Gene Therapy Market segmentation reflects a concerted effort towards innovation, where every segment contributes uniquely to the market dynamics and growth.
The anticipated market growth presents opportunities for collaboration across these sectors, fostering advancements that could reshape the landscape of healthcare globally, while charting new pathways for therapeutic solutions.
In the Cell and Gene Therapy Market, the regional segmentation showed distinct trends and valuations that highlighted significant opportunities for growth.
North America led the market, valued at 5.24 USD Billion in 2024, and is projected to grow to 18.81 USD Billion by 2035, showcasing its majority holding in this sector. The concentration of advanced Research and Development, along with robust healthcare infrastructure, reinforces North America's dominance.
Europe followed with a valuation of 3.42 USD Billion in 2024, anticipated to reach 12.32 USD Billion by 2035, driven by an increasing number of collaborations in Research and Development and an expanding patient population.
The Asia-Pacific (APAC) region was valued at 1.94 USD Billion in 2024, with projections of 6.73 USD Billion by 2035, as countries like China and India enhance their healthcare systems and regulatory frameworks. South America, while smaller, showed potential growth from 0.57 USD Billion in 2024 to 1.99 USD Billion by 2035, indicating rising interest in innovative therapeutics.
Meanwhile, the Middle East and Africa (MEA) segment started at 0.3 USD Billion in 2024, growing to 0.98 USD Billion by 2035, reflecting increasing investments in healthcare access and technology adaptation.
The Cell and Gene Therapy Market segmentation reflected a significant geographical disparity, driven by varying rates of technological adoption, investment levels, and healthcare policies in these regions.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Cell and Gene Therapy Market has emerged as a pivotal segment within the biotechnology and pharmaceuticals industry, driven by advancements in genetic engineering, personalized medicine, and increasing investments in research and development.
This market is characterized by its dynamic landscape, where innovative therapies targeting various diseases, including genetic disorders and cancers, are rapidly being developed. Competitive insights reveal a complex interplay between established pharmaceutical giants and agile biotech firms, each striving to enhance their therapeutic offerings and expand their market share.
As regulatory frameworks evolve and funding sources diversify, the market attracts significant attention from investors and stakeholders aiming to capitalize on the novel therapeutic solutions that promise improved patient outcomes and revolutionize treatment paradigms.
Intellia Therapeutics holds a notable position in the Cell and Gene Therapy Market, leveraging its cutting-edge CRISPR/Cas9 technology to develop transformative therapies. The company’s strengths lie in its innovative approach to gene editing, enabling precise modifications to target genes associated with various diseases.
Intellia Therapeutics has established a robust pipeline that includes therapies for genetic disorders and immunotherapies, reflecting its commitment to addressing unmet medical needs.
Additionally, the strategic partnerships that Intellia has formed with prominent research institutions and pharmaceutical companies amplify its research capabilities and resource access, thereby enhancing its competitive edge in the arena. Intellia's consistent focus on innovation and collaborative efforts positions it as a key player in advancing the field of gene therapy.
Roche is a significant contender within the Cell and Gene Therapy Market, recognized for its comprehensive portfolio that includes groundbreaking gene and cell therapies. The company boasts an impressive array of products targeted at various medical conditions, enriching its market presence with established therapies and novel options in development.
Roche’s strengths encompass its strong research and development framework, a commitment to precision medicine, and its integration of diagnostics with therapeutic solutions. The firm has engaged in strategic mergers and acquisitions, enhancing its capabilities and fostering innovation within the gene therapy space.
By expanding its existing pipeline and investing in next-generation therapeutic modalities, Roche aims to solidify its leadership position globally. Through its focused initiatives, Roche not only strengthens its market foothold but also contributes significantly to the advancements in treatment options available through cell and gene therapy.
The Cell and Gene Therapy Market has witnessed significant developments, particularly with advancements in technology and strategic collaborations among leading companies. Intellia Therapeutics has made strides in CRISPR-based therapies, while Roche has expanded its portfolio in gene therapies through partnerships with other firms.
Gilead Sciences is focusing on the development of its CAR T-cell therapies, driving growth and innovation in the market. AbbVie is actively pursuing acquisitions to enhance its capabilities in cell therapies, aligning with the recent trend of consolidation in the industry.
Furthermore, November 2022 saw Bristol Myers Squibb completing the acquisition of Celgene, which significantly bolstered its gene therapy portfolio. In terms of growth, Novartis has reported a substantial increase in its market valuation due to successful launches of its innovative therapies.
Spark Therapeutics and Bluebird Bio have also made headlines with their focused Research and Development initiatives aimed at addressing rare genetic disorders. The ongoing demand for advanced treatment options is catalyzing investments, fostering a competitive landscape, and ultimately accelerating the advancement of therapies that can potentially treat previously untreatable genetic conditions on a scale.
| Report Attribute/Metric | Details |
| Market Size 2023 | 9.34(USD Billion) |
| Market Size 2024 | 10.47(USD Billion) |
| Market Size 2035 | 37.0(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 12.16% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Intellia Therapeutics, Roche, Gilead Sciences, AbbVie, Bristol Myers Squibb, Sangamo Therapeutics, AveXis, Celyad, CRISPR Therapeutics, Kite Pharma, Novartis, Regeneron Pharmaceuticals, Spark Therapeutics, Bluebird Bio, Amgen |
| Segments Covered | Therapy Type, Application, End Use, Regional |
| Key Market Opportunities | Innovative treatment for rare diseases, Expanding applications in oncology, Increased investment in biopharmaceuticals, Advancements in gene editing technologies, Growing demand for personalized medicine |
| Key Market Dynamics | Rising prevalence of genetic disorders, Advances in CRISPR technology, Increased investment in R, Growing demand for personalized medicine, Expanding collaborations and partnerships |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Global Cell and Gene Therapy is market is anticipated to reach USD 67.89 billion at a CAGR of 18.12% during the forecast period of 2024 to 2032.
The US Cell and Gene Therapy Market is anticipated to reach USD 21.83 billion at a CAGR of 17.18 % during the forecast period of 2024 to 2032.
The Cell and Gene Therapy Market is expected to register a CAGR of 18.12% during the forecast period of 2024 to 2032.
The North America Cell and Gene Therapy Market accounted for USD 5.44 billion in 2023 and is expected to exhibit a 17.38% CAGR during the study period.
Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Aurion Biotech (US), Sarepta Therapeutics, Inc. (US), Ferring B.V. (Switzerland), Sibiono Genetech Co, Ltd., Shenzhen (Sibiono), Bluebird Bio, Inc. (US), Kite Pharmaceuticals, Inc. (US), Janssen Global Services (US)
The cell therapy segment held the majority share in 2023.
Which application holds the largest segment share in the Cell and Gene Therapy Market?
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
